CoronaVac vaccine

BIOLOGICAL4 trials

Sponsors

Hong Kong Sanatorium & Hospital, Clover Biopharmaceuticals AUS Pty, National Cancer Institute, Thailand, The University of Hong Kong

Conditions

COVID-19CancerCovid-19 Vaccine

Phase 3

Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

CompletedNCT05188677

Clover Biopharmaceuticals AUS PtyCOVID-19

Start: 2022-06-13End: 2023-06-06Updated: 2023-08-24

Unknown Phase

Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

CompletedNCT04898946

Hong Kong Sanatorium & HospitalCovid-19 Vaccine

Start: 2021-03-07End: 2021-12-31Updated: 2024-02-28

SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

CompletedNCT05313074

National Cancer Institute, ThailandCancer, COVID-19

Start: 2021-03-23End: 2022-02-25Updated: 2022-04-15

Community-based Sero-epidemiological Study of COVID-19

CompletedNCT05599555

The University of Hong KongCOVID-19

Start: 2022-04-28End: 2023-03-31Updated: 2024-12-11

Related Papers

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults

The Journal of Infectious Diseases2023-07-138 citations